Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yelena Yuriy Janjigian"'
Autor:
Anna M. Varghese, Juber Ahamad A Patel, Yelena Yuriy Janjigian, Fanli Meng, S Duygu Selcuklu, Catherine Zimel, David Michael Hyman, Gopa Iyer, Brian Houck-Loomis, Ghassan K. Abou-Alfa, Michael F. Berger, Maeve Aine Lowery
Publikováno v:
Journal of Clinical Oncology. 37:4096-4096
4096 Background: FGFR2 alterations are present in 14% of cholangiocarcinomas (CCA) and are promising targets of investigational FGFR-directed therapies. Cell-free DNA profiling has emerged as a non-invasive approach to monitor disease and longitudina
Autor:
Yelena Yuriy Janjigian, Yung-Jue Bang, Charles S. Fuchs, Shukui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric Van Cutsem, Z. Alexander Cao, Xinqun Chen, S. Peter Kang, Chie-Schin Shih, Hyun Cheol Chung
Publikováno v:
Journal of Clinical Oncology. 37:TPS4146-TPS4146
TPS4146 Background: Combination therapy with the anti-HER2 antibody trastuzumab with fluoropyrimidine and platinum is the current standard for patients with HER2+ mG/GEJc. We hypothesize that combination anti–PD-1 and anti-HER2 therapy will result
Autor:
Markus H. Moehler, Yelena Yuriy Janjigian, Antoine Adenis, Jean-Sebastien Aucoin, Narikazu Boku, Ian Chau, James M. Cleary, Kynan Tadao Feeney, Fabio A. Franke, Guillermo Ariel Mendez, Michael Schenker, Mingshun Li, Erika Hitre, Felix Couture, Michalis Karamouzis, Pierre-Luc Etienne, Jaffer A. Ajani
Publikováno v:
Journal of Clinical Oncology. 35:TPS4132-TPS4132
TPS4132 Background: Pts with adv G/GEJ cancer have an OS of ≈ 1 y, indicating an unmet medical need for new first-line treatments (Tx). Expression of the PD-1 ligands PD-L1/PD-L2 is observed in up to 40% of pts with G/GEJ cancer and is associated w
Autor:
Yelena Yuriy Janjigian, Marinela Capanu, Christopher M. Gromisch, David Paul Kelsen, Geoffrey Y. Ku, Karen T. Brown, Mark Schattner, David H. Ilson, David B. Solit, Michael F. Berger, Efsevia Vakiani
Publikováno v:
Journal of Clinical Oncology. 32:52-52
e15017 Background: Trastuzumab, approved by the FDA, has been the standard of care for pts with HER2-positive EG cancer. Resistance to trastuzumab is now emerging in this population. Afatinib, an oral inhibitor of EGFR, HER2, and HER4 has potent sing